

ASX Announcement

Results of General Meeting

Sydney Australia, 2 September 2026: In accordance with ASX Listing Rule 3.13.2 and section 251AA of the *Corporations Act 2001* (Cth), the results of the Recce Pharmaceuticals Limited (**ASX:RCE, FSE:R9Q**), General Meeting held today at 10:00AM (AEST) are attached.

All resolutions put to the General Meeting were decided by way of poll.

The Company is considering the options available to it following the failure to obtain shareholder approval for the proposed issue of Attaching Options and Piggyback Options to SPP participants at today's General Meeting.

This announcement has been approved for release by Recce Pharmaceuticals Board.

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.

The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce's efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Incentives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts' Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.

Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce's anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.



ASX: RCE, FSE: R9Q

Head Office: Level 15, 1 Farrer Place, Governor Macquarie Tower, SYDNEY NSW 2000 T +61 (2) 9000 1907

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 T +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

Disclosure of Proxy Votes

Recce Pharmaceuticals Ltd
General Meeting
Wednesday, 02 September 2026



AUTOMIC

Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Approval to issue Attaching Options and Piggyback Options to SPP participants (including under the SPP Shortfall Offer)	P	10,513,434	9,616,025 91.46%	802,695 7.63%	30,007,915	94,714 0.90%	9,770,055 19.24%	40,998,676 80.76%	30,007,915	Not Carried
2 Approval to issue Attaching Options and Piggyback Options to Dr John Prendergast, Director of the Company	P	34,796,773	33,889,364 97.39%	812,695 2.34%	22,765,155	94,714 0.27%	34,042,078 45.36%	41,009,992 54.64%	22,765,155	Not Carried
3 Approval to issue Attaching Options and Piggyback Options to Dr Alan Dunton, Director of the Company	P	35,192,228	34,183,819 97.13%	913,695 2.60%	22,369,700	94,714 0.27%	34,336,533 45.51%	41,110,992 54.49%	22,369,700	Not Carried
4 Approval to issue Attaching Options and Piggyback Options to Dr Justin Ward, Director of the Company	P	34,765,544	33,757,135 97.10%	913,695 2.63%	22,796,384	94,714 0.27%	33,909,849 45.20%	41,110,992 54.80%	22,796,384	Not Carried
5 Approval to issue Attaching Options and Piggyback Options to Mr James Graham, Director of the Company	P	28,366,152	27,357,743 96.45%	913,695 3.22%	29,195,776	94,714 0.33%	27,510,457 40.09%	41,110,992 59.91%	29,195,776	Not Carried
6 Ratification of Prior Issue of Placement Shares	P	34,432,585	33,519,578 97.35%	818,293 2.38%	22,644,700	94,714 0.28%	33,751,588 45.19%	40,936,294 54.81%	22,644,700	Not Carried

